SCHEMBL3057582

SCHEMBL3057582

O=C(NOCc1ccccc1)c1ccc(CNC(=O)c2cn3c4c(cccc24)CCC3)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.46
ALDH1A1 P00352 1/20 0.46
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
MTNR1A P48039 4/20 0.41
MTNR1B P49286 4/20 0.41
WDR5 P61964 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054218 0.86 HTT (0.49) HTTALDH1A1MAPTMEN1CYP3A4
SCHEMBL3048958 0.85 HDAC6 (0.52) HTTALDH1A1MTNR1AMTNR1B
SCHEMBL3054263 0.83 HTT (0.48) HTTALDH1A1MAPTMTNR1AMTNR1B
SCHEMBL3058774 0.82 MTNR1A (0.49) HTTALDH1A1MEN1KMT2AMTNR1A
SCHEMBL3060093 0.81 MTNR1A (0.48) ALDH1A1MEN1KMT2AMTNR1AMTNR1B
SCHEMBL3052990 0.81 MTNR1A (0.48) HTTALDH1A1MAPTMEN1KMT2A
SCHEMBL8078291 0.80 MTNR1A (0.46) HTTALDH1A1NPC1RAB9AMAPT
SCHEMBL8084507 0.77 RXRA (0.47) HTTALDH1A1MAPTMTNR1AMTNR1B
SCHEMBL3058587 0.76 MTNR1A (0.48) HTTALDH1A1MTNR1AMTNR1B
SCHEMBL3053168 0.76 MTNR1A (0.47) HTTALDH1A1MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261710-A1 HDAC Inhibitors ARQULE, INC. (US) 2010-10-14 US disclosed
US-20100261710-A1 HDAC Inhibitors ARQULE, INC. (US) 2010-10-14 US disclosed
US-20100261710-A1 HDAC Inhibitors ARQULE, INC. (US) 2010-10-14 US disclosed
WO-2009026446-A9 HDAC INHIBITORS ARQULE, INC. (US) 2010-03-11 WO disclosed
WO-2009026446-A2 HDAC INHIBITORS ARQULE, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261710-A1 HDAC Inhibitors HDAC5, HDAC1, HDAC4 HTT 296/4885ALDH1A1 667/4885NPC1 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.